City

Houston (1)

Tianjin (1)

Overall Status

Recruiting (1)

Withdrawn (1)

Phase

phase 1 (1)

phase 2 (1)

Sponsor

Institute of Hematology & Blood Diseases Hospital (1)

M.D. Anderson Cancer Center (1)

Collaborator

National Cancer Institute (NCI) (1)

Intervention

cytarabine (1)

dasatinib (1)

decitabine (1)

filgrastim-sndz (1)

fludarabine phosphate (1)

gemtuzumab ozogamicin (1)

idarubicin (1)

laboratory biomarker analysis (1)

Study Documents

Intervention Type

drug (2)

biological (1)

other (1)

Funder Type

Other (2)

Study Type

Interventional (2)

t(8;21)

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute

Recruiting

Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
+9 more

Cytarabine
+6 more

Houston, Texas

M D Anderson Cancer Center

Oct 27, 2021

Relapsed AML, T(8;21), C-KIT Mutation Trial in Tianjin (Dasatinib)

Withdrawn

Relapsed AML
+2 more

Dasatinib

Tianjin, Tianjin, China

HBDH

Mar 19, 2020